Zai Lab Q1 2026 revenue $99.6M (-6% YoY); net loss $51M; zoci shows 62.5% intracranial ORR

Zai Lab Ltd

2026-Q1 EPS reported -$0.05 revenue$99,611,000

Total revenues $99.6M, down 6% YoY; product revenue $95.6M (-10% YoY); ZEJULA fell to $30M from $49.5M.
Net loss $51M ($0.46/ADS); operating loss $69.4M; cash $761.3M at March 31.
Zoci (DLL3 ADC) delivered 62.5% confirmed intracranial ORR in SCLC brain mets at AACR; 38.2% ORR in epNECs.
Clinical collaborations with Amgen and Boehringer Ingelheim to evaluate zoci combinations in SCLC and NECs.
Appointed Yizhe Wang, Ph.D., as Operating Partner; KarXT launch preparations underway; TIVDAK under regulatory review.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Zai Lab Ltd reported the first quarter of 2026 results: revenue $99.6 million, net income Net loss was $51.0 million, EPS loss per ADS of $0.46.

Period: the first quarter of 2026
Revenue: $99.6 million
Net income: Net loss was $51.0 million
EPS: loss per ADS of $0.46
Result: reported results

Exact text from the filing

forth by specific reference in such filing. --- EX-99.1 (EX-99.1) --- Zai Lab Announces First Quarter 2026 Financial Results and Recent Corporate Updates – Total revenues of $99.6 million for the first quarter of 2026, reflecting anticipated first-quarter dynamics, including certain competitive impacts for ZEJULA and pricing adjustment related to NRDL renewal for

View on SEC.gov

18 earnings releases filed in the last 30 days. Browse all earnings releases →

Zai Lab Ltd filing history →

Source: SEC EDGAR

accession 0001628280-26-031624

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.